ArticlePakistan journal of medical sciences2025
Assessment of the feasibility and safety of totally implantable venous access port to collect blood samples in pediatric patients with acute lymphoblastic leukemia.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the feasibility and safety of utilizing a totally implantable venous access port (TIVAP) to collect venous blood sample as an alternative to peripheral venipuncture in pediatric patients with acute lymphoblastic leukemia (ALL). Method: The study implemented a self-contemporaneous control design. Fifty pediatric patients diagnosed with ALL were recruited from a tertiary children's hospital between January to November 2024 in Hangzhou, China. They underwent high-dose methotrexate (HD-MTX) chemotherapy. For each participant, both TIVAP and peripheral venipuncture were used to collect blood samples. The MTX concentration, levels of blood indicators, coagulation function and adverse events were measured and compared between TIVAP and peripheral venipuncture groups. Results: The mean age was 6.1 (standard deviation: 2.9) years. No statistically significant difference in MTX plasma concentration was observed between TIVAP and peripheral venipuncture group at 24, 48, and 72 hours in all patients and subgroups of low, intermediate and high risk ( Conclusions: TIVAP had a comparable feasibility and safety with peripheral venipuncture, and may be used as an alternative to collect blood sample in pediatric patients with ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.